Some content of this application is unavailable at the moment.
If this situation persist, please contact us atFeedback&Contact
1. (WO2019062435) USE OF TRIAZOLOPYRIMIDINE, TRIAZOLOPYRIDINE COMPOUNDS AND COMPOSITION THEREOF FOR TREATING PRC2-MEDIATED DISEASES
Latest bibliographic data on file with the International Bureau    Submit observation

Pub. No.: WO/2019/062435 International Application No.: PCT/CN2018/102833
Publication Date: 04.04.2019 International Filing Date: 29.08.2018
IPC:
C07D 487/04 (2006.01) ,A61P 35/00 (2006.01) ,A61K 31/519 (2006.01) ,A61K 31/5377 (2006.01) ,A61K 31/541 (2006.01) ,A61K 31/551 (2006.01) ,A61P 35/02 (2006.01)
C CHEMISTRY; METALLURGY
07
ORGANIC CHEMISTRY
D
HETEROCYCLIC COMPOUNDS
487
Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/-C07D477/183
02
in which the condensed system contains two hetero rings
04
Ortho-condensed systems
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
P
SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
35
Antineoplastic agents
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
K
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31
Medicinal preparations containing organic active ingredients
33
Heterocyclic compounds
395
having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
495
having six-membered rings with two nitrogen atoms as the only ring hetero atoms, e.g. piperazine
505
Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
519
ortho- or peri-condensed with heterocyclic rings
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
K
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31
Medicinal preparations containing organic active ingredients
33
Heterocyclic compounds
395
having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
535
having six-membered rings with at least one nitrogen and at least one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
5375
1,4-Oxazines, e.g. morpholine
5377
not condensed and containing further heterocyclic rings, e.g. timolol
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
K
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31
Medicinal preparations containing organic active ingredients
33
Heterocyclic compounds
395
having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
54
having six-membered rings with at least one nitrogen and at least one sulfur as the ring hetero atoms, e.g. sulthiame
541
Non-condensed thiazines containing further heterocyclic rings
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
K
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31
Medicinal preparations containing organic active ingredients
33
Heterocyclic compounds
395
having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
55
having seven-membered rings, e.g. azelastine, pentylenetetrazole
551
having two nitrogens as ring hetero atoms, e.g. clozapine, dilazep
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
P
SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
35
Antineoplastic agents
02
specific for leukemia
Applicants:
中国科学院上海药物研究所 SHANGHAI INSTITUTE OF MATERIA MEDICA, CHINESE ACADEMY OF SCIENCES [CN/CN]; 中国上海市 浦东张江祖冲之路555号 555 Zu Chong Zhi Road, Zhang Jiang, Pudong Shanghai 201203, CN
苏州苏领生物医药有限公司 SUZHOU SUPLEAD LIFE SCIENCES CO., LTD. [CN/CN]; 中国江苏省苏州市 苏州工业园区若水路398号D栋10楼 10th Floor, Building No. 398, Ruoshui Road, Suzhou Industrial Park Suzhou, Jiangsu 215123, CN
Inventors:
周兵 ZHOU, Bing; CN
罗成 LUO, Cheng; CN
杨亚玺 YANG, Yaxi; CN
张元元 ZHANG, Yuanyuan; CN
杜道海 DU, Daohai; CN
蒋华良 JIANG, Hualiang; CN
乔刚 QIAO, Gang; CN
王新俊 WANG, Xinjun; CN
Agent:
北京金信知识产权代理有限公司 KINGSOUND & PARTNERS; 中国北京市 海淀区紫竹院路116号嘉豪国际中心B座11层 11/F, Block B, KingSound International Center 116 Zizhuyuan Road, Haidian District Beijing 100097, CN
Priority Data:
201710898099.528.09.2017CN
201711408714.622.12.2017CN
Title (EN) USE OF TRIAZOLOPYRIMIDINE, TRIAZOLOPYRIDINE COMPOUNDS AND COMPOSITION THEREOF FOR TREATING PRC2-MEDIATED DISEASES
(FR) UTILISATION DE TRIAZOLOPYRIMIDINE, DE COMPOSÉS DE TRIAZOLOPYRIDINE ET D'UNE COMPOSITION DE CEUX-CI POUR LE TRAITEMENT DE MALADIES MÉDIÉES PAR PRC2
(ZH) 三氮唑并嘧啶、三氮唑并吡啶化合物及其组合物用于治疗PRC2介导的疾病
Abstract:
(EN) Provided in the present invention are a compound represented by general formula I, a pharmaceutically acceptable salt, enantiomer, diastereoisomer or racemate thereof, a preparation method therefor, a pharmaceutical composition containing same, and a use of same in the preparation of drugs for treating diseases or conditions mediated by EED and/or PRC2. The compound of the present invention can be used for treating PRC2-mediated diseases or conditions. (I)
(FR) La présente invention concerne un composé représenté par la formule générale I, un sel pharmaceutiquement acceptable, un énantiomère, un diastéréoisomère ou un racémate de celui-ci, un procédé de préparation associé, une composition pharmaceutique contenant ceux-ci et une utilisation de ceux-ci dans la préparation de médicaments pour le traitement de maladies ou affections médiées par EED et/ou PRC2. Le composé selon la présente invention peut être utilisé pour le traitement de maladies ou affections médiées par PRC2. (I)
(ZH) 本发明提供了一种由通式I表示的化合物、其可药用的盐、对映异构体、非对映异构体或外消旋体,其制备方法,包含其的药物组合物,以及其在制备用于治疗由EED和/或PRC2介导的疾病或病症的药物中的用途。本发明所述的化合物可用于治疗由PRC2介导的疾病或病症。(I)
front page image
Designated States: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW
African Regional Intellectual Property Organization (ARIPO) (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW)
Eurasian Patent Office (AM, AZ, BY, KG, KZ, RU, TJ, TM)
European Patent Office (EPO) (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR)
African Intellectual Property Organization (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG)
Publication Language: Chinese (ZH)
Filing Language: Chinese (ZH)